Long-term efficacy of vedolizumab for ulcerative colitis

Journal of Crohn's and Colitis

Volumn 11, Issue 4, 2017, Pages 400-411

  Loftus, Edward V ^a   Colombel, Jean Frédéric ^b   Feagan, Brian G ^c   Vermeire, Severine ^d   Sandborn, William J ^e   Sands, Bruce E ^b   Danese, Silvio ^f   D'Haens, Geert R ^g   Kaser, Arthur ^h   Panaccione, Remo ⁱ   Rubin, David T ^j   Shafran, Ira ^k   McAuliffe, Megan ^l   Kaviya, Arpeat ^m   Sankoh, Serap ^l   Mody, Reema ⁿ   Abhyankar, Brihad ^m   Smythm, Michael ^m  

^a MAYO CLINIC   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j UNIVERSITY OF CHICAGO   (United States)

^k Shafran Gastroenterology Center   (United States)

^l TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^m Takeda Global Research and Development Centre Europe   (United Kingdom)

ⁿ Takeda Pharmaceuticals International Inc   (United States)

more..

Author keywords

Long term efficacy; Ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID DERIVATIVE; EFALIZUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; BREAST CARCINOMA IN SITU; BRONCHITIS; CLINICAL OUTCOME; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; INFUSION RELATED REACTION; KIDNEY CANCER; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; OPEN STUDY; OROPHARYNX PAIN; PARTIAL MAYO SCORE; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RHINOPHARYNGITIS; SCORING SYSTEM; SINUSITIS; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION; CLINICAL TRIAL; COLITIS, ULCERATIVE; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 85019608509     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw177     Document Type: Article

References (30)

1. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-19.
2. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478.
3. Wang Y, MacDonald JK, Vandermeer B, Griffiths AM, El-Matary W. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;8:CD007560.
4. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98.
5. Carter MJ, Lobo AJ, Travis SP, IBD Section Bristish Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53:v1-v16.
6. Akobeng AA, Sandborn WJ, Bickston SJ, et al. Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane reviews tell us? Inflamm Bowel Dis 2014;20:2132-41.
7. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107:1409-22.
8. Garnock-Jones KP. Vedolizumab: A review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. BioDrugs 2015;29:57-67.
9. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
10. Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the a4ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18:2107-19.
11. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-a4ß7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75.
12. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin a4ß7. Gastroenterology 1996;111:1373-80.
13. Wyant T, Estevam J, Yang L, Rosario M. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 2016;90:168-76.
14. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
15. World Medical Association. World Medical Association [WMA] Declaration of Helsinki -ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ Accessed December 22, 2014.
16. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9.
17. Clifford D, McAuliffe M, Stephens K, et al. Risk assessment and minimization for progressive multifocal leukoencephalopathy (PML) (RAMP): A program to assess the potential early signs and symptoms of PML during clinical development of vedolizumab. Am J Gastroenterol 2013;108:S502.
18. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.
19. Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment Pharmacol Ther 2009;29:1032-41.
20. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42:188-202.
21. Loftus EV, Siegel C, Panaccione R, et al. Corticosteroid dose reduction in ulcerative colitis patients treated with vedolizumab during the GEMINI 1 trial. Am J Gastroenterol 2015;110:S790.
22. Pallis AG, Mouzas IA, Vlachonikolis IG. The Inflammatory Bowel Disease Questionnaire: A review of its national validation studies. Inflamm Bowel Dis 2004;10:261-9.
23. Konig HH, Ulshofer A, Gregor M, et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:1205-15.
24. McColl E, Han SW, Barton JR, Welfare MR. A comparison of the discriminatory power of the Inflammatory Bowel Disease Questionnaire and the SF-36 in people with ulcerative colitis. Qual Life Res 2004;13:805-11.
25. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24-30.
26. Takeda. Entyvio (vedolizumab) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2014.
27. Sands BE, Dubinsky M, Vermeire S, et al. Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2014;109:S478-S9.
28. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
29. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
30. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016. doi: 10.1136/ gutjnl-2015-311079. [Epub ahead of print].